Cargando…

Transcriptional profiling demonstrates altered characteristics of CD8 (+) cytotoxic T‐cells and regulatory T‐cells in TP53‐mutated acute myeloid leukemia

BACKGROUND: Acute myeloid leukemia (AML) patients have limited effect from T‐cell‐based therapies, such as PD‐1 and CTLA‐4 blockade. However, recent data indicate that AML patients with TP53 mutation have higher immune infiltration and other immunomodulatory therapies could thus potentially be effec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abolhalaj, Milad, Sincic, Viktor, Lilljebjörn, Henrik, Sandén, Carl, Aab, Alar, Hägerbrand, Karin, Ellmark, Peter, Borrebaeck, Carl A. K., Fioretos, Thoas, Lundberg, Kristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359873/ https://www.ncbi.nlm.nih.gov/pubmed/35297213 http://dx.doi.org/10.1002/cam4.4661

Ejemplares similares

IL1RAP is expressed in several subtypes of pediatric acute lymphoblastic leukemia and can be used as a target to eliminate ETV6::RUNX1-positive leukemia cells in preclinical models
por: Ågerstam, Helena, et al.
Publicado: (2022)

Integrative analysis of gene expression and copy number alterations using canonical correlation analysis
por: Soneson, Charlotte, et al.
Publicado: (2010)

CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting
por: Landberg, Niklas, et al.
Publicado: (2018)

A high-content cytokine screen identifies myostatin propeptide as a positive regulator of primitive chronic myeloid leukemia cells
por: von Palffy, Sofia, et al.
Publicado: (2020)

Clonal competition within complex evolutionary hierarchies shapes AML over time
por: Sandén, Carl, et al.
Publicado: (2020)

Clonal conversion of B lymphoid leukemia reveals cross-lineage transfer of malignant states
por: Somasundaram, Rajesh, et al.
Publicado: (2016)

Arrayed molecular barcoding identifies TNFSF13 as a positive regulator of acute myeloid leukemia-initiating cells
por: Chapellier, Marion, et al.
Publicado: (2019)

Why B(-)other? About the gap of unknowns in ALL
por: Fioretos, Thoas
Publicado: (2022)

Whole-exome sequencing exploration of acquired uniparental disomies in B-cell precursor acute lymphoblastic leukemia
por: Lundin-Ström, Kristina B., et al.
Publicado: (2018)

Combinatorial molecule screening identified a novel diterpene and the BET inhibitor CPI-203 as differentiation inducers of primary acute myeloid leukemia cells
por: Hultmark, Simon, et al.
Publicado: (2020)

Profiling dendritic cell subsets in head and neck squamous cell tonsillar cancer and benign tonsils
por: Abolhalaj, Milad, et al.
Publicado: (2018)

Inducing synthetic lethality for selective targeting of acute myeloid leukemia cells harboring STAG2 mutations
por: Subramaniam, Agatheeswaran, et al.
Publicado: (2022)

The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML
por: von Palffy, Sofia, et al.
Publicado: (2022)

Transgenic expression of human cytokines in immunodeficient mice does not facilitate myeloid expansion of BCR-ABL1 transduced human cord blood cells
por: Askmyr, Maria, et al.
Publicado: (2017)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Expression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53(null) Cell Lines
por: Silden, Elisabeth, et al.
Publicado: (2013)

Gene expression signatures in childhood acute leukemias are largely unique and distinct from those of normal tissues and other malignancies
por: Andersson, Anna, et al.
Publicado: (2010)

PAX5 is part of a functional transcription factor network targeted in lymphoid leukemia
por: Okuyama, Kazuki, et al.
Publicado: (2019)

TP53 inhibitor PFTα increases the sensitivity of arsenic trioxide in TP53 wildtype tumor cells
por: Wang, Haiwei, et al.
Publicado: (2022)

Mutation, methylation, and gene expression profiles in dup(1q)-positive pediatric B-cell precursor acute lymphoblastic leukemia
por: Gunnarsson, Rebeqa, et al.
Publicado: (2018)

Synergistic effects of agonistic costimulatory antibodies adsorbed to amphiphilic poly(γ-glutamic acid) nanoparticles
por: Freiburghaus, Catja, et al.
Publicado: (2013)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Analysis of Tp53 Codon 72 Polymorphisms, Tp53 Mutations, and HPV Infection in Cutaneous Squamous Cell Carcinomas
por: Loeb, Keith R., et al.
Publicado: (2012)

TP53 Mutations in Nonsmall Cell Lung Cancer
por: Mogi, Akira, et al.
Publicado: (2011)

TP53 mutations on circulating cell-free DNA
por: Pantel, Klaus
Publicado: (2016)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

TP53 codon 72 polymorphism affects accumulation of mtDNA damage in human cells
por: Altilia, Serena, et al.
Publicado: (2012)

An improved method for detecting and delineating genomic regions with altered gene expression in cancer
por: Nilsson, Björn, et al.
Publicado: (2008)

Threshold-free high-power methods for the ontological analysis of genome-wide gene-expression studies
por: Nilsson, Björn, et al.
Publicado: (2007)

Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia
por: Woll, Petter S., et al.
Publicado: (2022)

The TP53 fertility network
por: Paskulin, Diego d’Avila, et al.
Publicado: (2012)

TP53: an oncogene in disguise
por: Soussi, T, et al.
Publicado: (2015)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53
por: Abrams, Stephen L., et al.
Publicado: (2022)

The impact of chemotherapeutic drugs on the CYP1A1-catalysed metabolism of the environmental carcinogen benzo[a]pyrene: Effects in human colorectal HCT116 TP53(+/+), TP53(+/−) and TP53(−/−) cells
por: Willis, Alexandra J., et al.
Publicado: (2018)

Unique volatolomic signatures of TP53 and KRAS in lung cells
por: Davies, M P A, et al.
Publicado: (2014)

CRISPR screens are feasible in TP53 wild‐type cells
por: Brown, Kevin R, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vk6sft78sqoost1iglriaqiece